To determine whether altered cholinergic neurotransmission can modify the long-term secretion of amyloid precursor protein (APP), endogenous levels of APP and nerve growth factor (NGF), we administered a selective M1 muscarinic receptor agonist (RS86) or the muscarinic antagonist, atropine, for 7 days in vivo into young adult mice (C57BL/6j). The levels of NGF and total APP in the hippocampus, frontal cortex, striatum, parietal cortex and cerebrospinal¯uid (CSF) were examined by ELISA and Western blot. We found that this repeated i.m. administration of M1 receptor agonist resulted in decreased total APP levels in the hippocampus, frontal cortex and parietal cortex, and increased secreted a-APPs levels in the CSF. M1 agonist treatment also resulted in decreased NGF levels in the hippocampus and CSF. These effects of the M1 muscarinic agonist could be blocked by atropine, which by itself elevated tissue levels of total APP. Interestingly, we found that the decrease of total APP in the hippocampus and striatum after M1 agonist treatment inversely correlated with the change in NGF levels. These data suggest that a sustained increased cholinergic, M1-mediated neurotransmission will enhance secretion of a-APPs in CSF and adaptively reduce the levels of total APP and NGF in the corticohippocampal regions of normal mice. The dynamic and adaptive regulation linking total APP and NGF levels in normal adult mice is relevant for understanding the pathophysiology of conditions with cholinergic and APP related pathologies, like Alzheimer's disease and Down's syndrome.
Introduction
Alzheimer's disease (AD) is a severe cognitive disorder associated with degenerative changes in the cholinergic system (Bartus et al., 1982; Coyle et al., 1983) . The loss of cholinergic neurons in the basal forebrain contributes to the progressive memory loss in AD patients. One of the major neuropathological features of AD is extracellular amyloid-beta (Ab) deposits in senile neuritic plaques. The major component of neuritic plaques is a 39±43 amino acid, Ab peptide (Glenner et al., 1984; Masters et al., 1985) , derived from the proteolytic cleavage of the membrane bound glycoprotein, amyloid precursor protein (APP) (Kang et al., 1987; Tanzi et al., 1987) . Several alternative proteolytic mechanisms have been identi®ed: in the secretory pathway (nonamyloidogenic pathway), cleavage of APP at position 16±17 or the Ab segment generates a large soluble ectodomain of APP (a-APPs) and a 10-kDa membrane associated Cterminal fragment (Esch et al., 1990) ; in the amyloidogenic pathway, cleavage of APP at both the N-terminus (b-secretase) and C-terminus (g-secretase) of the Ab domain, yields the Ab peptide which easily aggregate and form amyloid and b-APPs Haass et al., 1992; Shoji et al., 1992; Haass et al., 1993) .
A majority of reports demonstrate that increased a-APPs secretion is associated with a reduction in Ab generation, suggesting a reciprocal regulation of processing between a-APPs and Ab formation (Busciglio et al., 1993a; Busciglio et al., 1993b; Gabuzda et al., 1993) . A number of biological functions for a-APPs have been reported such as neuroprotective and neurotrophic effects (Whitson et al., 1989; Mattson et al., 1993) , neurite outgrowth (Saiton et al., 1989; Milward et al., 1992; Clarris et al., 1994) , cell proliferation (Saiton et al., 1989) , promotion of cell±substratum adhesion (Schubert et al., 1989; Breen et al., 1991; Chen & Yankner, 1991) , and the prevention of intracellular calcium accumulation and cell death (Mattson et al., 1993) . The mechanisms that regulate this pathway of APP processing and the physiological actions of a-APPs are not well understood. , found that the stimulation of phosphoinositide-linked M1 and M3 mAChR, stably transfected into human embryonic kidney cells, increases the a-APPs, which is controlled by protein kinase C (PKC)-coupled mAChR activation Buxbaum et al., 1993; Hung et al., 1993; Slack et al., 1993; Nitsch & Growdon, 1994; Caputi et al., 1997) . Elevated release of aAPPs by receptor stimulation is not affected by protein synthesis inhibitors, indicating that pre-existing APP is cleaved . However, increased APP processing by PKC activation is independent of direct APP phosphorylation, indicating that other proteins may be involved in APP processing (Hung & Selkoe, 1994) .
Nerve growth factor (NGF) regulates the survival, differentiation, and phenotypic maintenance of cholinergic basal forebrain neurons and also neuronal plasticity after injury (Korsching et al., 1985; Whittemore et al., 1986; Whittemore et al., 1988; Conner et al., 1992) . Nerve growth factor is highly expressed in major targets of the ascending projection from cholinergic basal forebrain neurons (Bigl et al., 1982; Mesulam et al., 1983 ) that transport (retrogradely) NGF from these areas to the cholinergic cell bodies of the basal forebrain (Seiler & Schwab, 1984) . After cortical/hippocampal release, NGF mediates its actions on cholinergic basal forebrain neurons via the low-af®nity p75 NTR and the NGF-speci®c TrkA (tyrosine receptor kinase A) receptor (Bickel & Kewitz, 1990; Lauterborn et al., 1991; Gibs & Pfaff, 1994) .
NGF treatment in vitro increases total APP mRNA levels, APP expression levels, and secretion of a-APPs (Smith et al., 1991; Fukuyama et al., 1993) . Exogenous NGF treatment increases choline acetyltransferase (ChAT) activity and choline uptake activities, enhances acetylcholine synthesis and also basal and depolarizationinduced acetylcholine release in adult rat (Rylett et al., 1993) . Conversely, there are several data suggesting a cholinergic mechanism in the regulation of cortical/hippocampal NGF synthesis and release (Yu et al., 1995; Yu et al., 1996; Rossner et al., 1997) . Recent studies provide a better understanding of the cholinergic effects and adaptive regulation of NGF levels and APP in postsynaptic target areas of the hippocampus and cortical cortex (Isacson et al. 2002) .
Curiously, in AD, hippocampal NGF levels have variably been shown to be either increased or not signi®cantly changed (Goedert et al., 1986; Crutcher et al., 1993; Mufson et al., 1995; Fahnestock et al., 1996) . This is explained by a disease progression dependent response at later stages of cholinergic synapse loss. At some ADstages and ageing stages, there is potentially a reduced retrograde transport of NGF leading to accumulation of NGF in the hippocampal tissue (Cooper et al., 1994; Mufson et al., 1995; Cooper et al. 2001) . To determine whether increased or decreased cholinergic muscarinic function can modify a-APPs secretion and the levels of APP and NGF in vivo, we examined the effects of chronic treatment with an M1 muscarinic agonist, RS86, compared with a general muscarinic antagonist, atropine, in the hippocampus, frontal cortex, striatum, parietal cortex brain regions and CSF of normal mice.
Materials and methods
All experiments were performed in accordance with Institutional Animal Care and Use Committee (IACUC), McLean Hospital, guidelines.
Experimental design

Experiment 1
A total of 16 young adult female C57BL/6J mice (18±21 g, Jackson Laboratories, Bar Harbor, ME) were treated with the selective M1 agonist, RS86, for 1 week. A total of 16 adult female C57BL/6J mice were treated with saline as a control group.
Experiment 2
Normal adult female C57BL/6J mice were divided into four balanced groups for pretreatment with a muscarinic receptor antagonist, atropine, or vehicle before treatment with the M1 agonist; saline plus M1 agonist (n = 16), atropine plus M1 agonist (n = 16), atropine (n = 16), saline (n = 16). After 7 days of drug treatment, CSF was collected and mice were killed for brain dissection.
Muscarinic receptor agonist treatment RS86 (gift from Novartis, Switzerland) is a selective muscarinic M1 receptor agonist (Palacios et al., 1986; Wanibuchi et al., 1990; Rupniak et al., 1992) . Based on our previous studies (Lin et al., 1999) , animals in all experiments reported here were injected twice daily with the following doses: 1.5 mg/kg i.m. at approximately 09.00 h and 2.0 mg/kg i.m. 8 h later, for seven consecutive days.
Control animals received an equal volume of saline (i.m.) at the same time intervals as the M1 agonist-treated groups. All injections were performed at the same time points every day throughout the experiments.
Muscarinic receptor antagonist treatment
Animals were preinjected with the muscarinic receptor antagonist, atropine (Sigma, St. Louis, MO), 20 min prior to RS86 injection (1.5 mg/kg, i.m. at 09.00 h and 2 mg/kg, i.m. 8 h later), twice daily with the following doses: 8 mg/kg s.c. at approximately 08.40 h and 12 mg/kg s.c. 8 h later, for seven consecutive days (modi®ed from Lin et al., 1999) . Control animals received an equal volume of saline (i.m.) at the same time intervals as the antagonist and agonist-treated groups. All injections were performed at the same time points every day throughout the experiments.
Post-mortem procedures
Immediately prior to being killed, mice from all groups were placed in a mouse stereotaxic apparatus under anaesthesia with sodium pentobarbital (50 mg/kg i.p., Sigma Chemicals, St Louis, MO). The occipital foramen was exposed and CSF was collected from the cisterna magna with a 20-mL pipette with a long¯exible tip. The collected CSF (~20 mL) was frozen on dry ice and stored at ±70°C for use in Western blot and NGF ELISA assays. The brains were then removed and dissected on ice. Tissue samples from the hippocampus, frontal cortex, striatum and parietal cortex were taken for Western blot and NGF ELISA assays.
Western blots for APP protein detection
The antibody, 22C11 (Boehringer Mannheim, Indianapolis, IN), raised against an N-terminal epitope of APP was used to determine the total APP in protein extracts obtained from the brain tissues and the a-APPs level in the CSF (Lin et al., 1999) . In some cases (see Results), a monoclonal antibody,`Jonas', directed against residues 643±695 in the C-terminus of APP (Boehringer Mannheim, Indianapolis, IN), was used to demonstrate the absence of C-terminus in a-APPs in CSF. The tissue was homogenized using a hand-held homogenizer with cell lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10 mg/mL Aprotinin, 25 mg/ mL Leupeptin, 10 mg/mL Pepstatin, 1 mM PMSF; all protease inhibitors purchased from Sigma Chemicals, St Louis, MO) and then sonicated. Homogenates were centrifuged at 14 000 Q g for 30 min at 4°C. The supernatant was collected and aliquots were stored at ±70°C. The protein levels were determined using Bio-Rad Protein Assay (BIO-RAD, Hercules, CA). Samples containing equal amounts of total protein were boiled with SDS sample buffer and electrophoresed on 10% SDS±polyacrylamide gels. Proteins were electrophoretically transferred to polyvinylidene di¯uoride (PVDF) membranes (BIO-RAD, Hercules, CA). Membranes were blocked with 2.5% nonfat dried milk in 0.05 M Tris-buffered saline (pH 7.4) with 0.1% Tween 20 (TBS-T) and then incubated with the 22C11 antibody (1 : 500) in 1% nonfat dried milk in TBST overnight at 4°C. After the incubation with the secondary horseradish peroxidase (HRP)-linked anti-mouse IgG antibody (dilution 1 : 6000, Jackson Laboratory, Bar Harbor, ME) in 0.25% nonfat dried milk in TBST, the membranes were visualized by enhanced chemiluminescence (Amersham, Arlington Heights, IL) using Kodak X-omat ®lms (Kodak, Rochester, NY).
Madison, WI (Zettler et al., 1996) ]. Brie¯y, a polystyrene coated ELISA plate was incubated overnight at 4°C with the polyclonal anti-NGF antibody (1 : 1000 dilution). Non-speci®c binding was blocked by incubating the plate with serum albumin for 1 h at room temperature and washed with 0.1% TBS-T once. A standard curve was created from serial dilutions of known concentrations of NGF. Samples were dispensed into the remaining wells and the plate was incubated for 6 h at room temperature. The plate was then washed with 0.1% TBS-T ®ve times, followed by incubation with the monoclonal anti-NGF antibody (1 : 4000 dilution) overnight. After rinsing the plate ®ve times, samples were incubated in the HRP conjugated tertiary anti-rat antibody (1 : 2000 dilution) solution for 2.5 h at room temperature. After rinsing the plate ®ve times, a TMB solution/peroxidase substrate mixture was added to the wells. The reaction was allowed to proceed for 10 min and stopped with 1 M phosphoric acid. The ELISA plate was then read using a Labsystem Multiscan Plus plate reader set at 450 nm wavelength.
Densitometric analysis
Quanti®cation of the APP immunoreactive bands was performed using densitometry. Films of the Western blots were scanned (Scanner UMAX ASTRA 1200S) using Adobe Photoshop (version 5.5, Adobe Systems) and the optical density (OD) of the APP bands was measured using NIH Image (Version 1.61). The relative APP values were calculated by subtracting the background OD-value from the measured OD of the APP bands. The results were con®rmed by duplicate measurements of the same sample.
Statistical analysis
All statistical analyses were carried out using JMP (version 3.1.6, SAS Institute). Data from Western blots and ELISAs were compared between different groups for each brain region with an unpaired student's t-test and differences between groups were considered statistically signi®cant when P < 0.05. Regression analyses were performed with a linear ®t for two independent variables (JMP, version 3.1.6, SAS Institute).
Results
Effects of a selective M1 muscarinic receptor agonist (RS86) on the levels of APP and NGF To determine the effects of a selective M1 muscarinic receptor agonist on the levels and secretory processing of APP and NGF, a group of young normal mice was treated with the muscarinic receptor agonist (RS86, 3.5 mg/kg per day, i.m. for 7 days). Western blot analysis revealed that total APP levels were signi®cantly reduced to 84% (P = 0.04) in the hippocampus, 82% (P = 0.02) in the frontal cortex, and 91% (P = 0.03) in the parietal cortex of normal mice treated with M1 agonist compared to those treated with vehicle (saline) ( Table 1 ). No such change was found in the striatum (Table 1) . The levels of a-APPs in the CSF in animals treated with vehicle or M1 muscarinic receptor agonist were detected using Western blot analysis with the 22C11 antibody. The levels of a-APPs in the CSF in animals treated with M1 agonist were signi®cantly increased to 180% (P = 0.01) compared to a-APPs levels in the CSF in vehicle treated control animals (Fig. 1) . In order to con®rm that the a-APPs detected with the 22C11 antibody in the CSF was the secreted N-terminal derivative of APP, a C-terminal (643±695) speci®c antibody`Jonas' was used to examine full-length APP levels in the CSF. No obvious immunoreactive bands were found in the CSF with this antibody [data not shown, and (Lin et al., 1999) ], demonstrating that a-APPs in the CSF lacks the C-terminus, as described previously (Palmert et al., 1989) .
In the same group of normal mice treated with the M1 muscarinic agonist, ELISA analysis revealed that NGF protein levels were reduced to 54% (P = 0.02) in hippocampus (Table 1) and 73% (P = 0.04) in CSF (Fig. 1) compared to levels seen in vehicle-treated controls. In this experiment, NGF protein levels in the hippocampus of normal mice was approximately 8 ng/g of wet tissue for the value of 100% in hippocampus in Table 1 . No signi®cant changes in NGF levels were found in the frontal cortex, parietal cortex or striatum in any of three experimental groups (Table 1) .
Effects of a muscarinic receptor antagonist (atropine) on the levels and secretion of APP and NGF in normal mice
To investigate the effects of a broad muscarinic receptor antagonist on total APP and NGF levels, atropine was given to normal mice (20 mg/kg per day, s.c. for 7 days, Lin et al., 1999) . Following atropine treatment, total APP levels were signi®cantly increased to 202% (P < 0.0001) in the hippocampus, 129% (P < 0.0001) in the frontal cortex, and 119% (P < 0.001) in the parietal cortex compared to vehicle-treated controls (Table 1) . No such changes in total APP levels were found in the striatum (Table 1) . The levels of a-APPs in the CSF were decreased to 38% (P = 0.05) of control (Fig. 1) by atropine treatment. Atropine treatment did not signi®cantly alter NGF protein levels in any of the four brain tissue regions or CSF (Fig. 1) . Atropine blocks the effect of the M1 muscarinic receptor agonist (RS86)
To further study the interactions of muscarinic activation or blockade on total APP and NGF levels, normal mice were treated concomitantly with atropine and RS86. Comparing atropine plus M1 agonist treatment to saline plus RS86 treatment showed that atropine signi®cantly reversed the reduction of total APP levels in hippocampus caused by M1 agonist (Table 1 ). The change in total APP levels by treatment with M1 agonist plus atropine was also signi®cant when compared to atropine treatment alone. In the frontal cortex and striatum, no signi®cant changes in total APP levels were found between the atropine plus M1 agonist and saline plus M1 agonist treatment groups (Table 1) . Atropine plus M1 agonist treatment did not signi®cantly change NGF levels in any of the four tissue regions or CSF (Table 1 and Fig. 1 ).
Relative changes of APP and NGF levels by muscarinic agonist treatment in individual mice
To determine whether the effects of the selective M1 agonist on total APP and NGF levels were interrelated in individual animals, we did a regression analysis on the data for total APP and NGF levels. In the hippocampus of normal mice treated with the M1 agonist, the percentage decrease in total APP levels was inversely related to the percentage decrease in NGF levels ( Fig. 2A , regression analysis: n = 16; P = 0.01), suggesting a stable relationship between the regulation of APP and NGF levels by M1 muscarinic receptor   FIG. 2 . Correlation of the changes in total APP levels and NGF levels by M1 muscarinic agonist (RS86) treatment in the hippocampus from individual mice (regression analysis: n = 16, P = 0.01 in the hippocampus; n = 14, P < 0.05 in the striatum). The changes in total APP levels were inversely related to the changes in NGF levels in the hippocampus and striatum of normal mice treated with an M1 agonist. The total APP and NGF values are indicated as percentage decrease from control mean value. The treatment with RS86 increased a-APPs level in the CSF to 180% of control (P = 0.01) and decreased NGF levels to 73% of control (P = 0.04) in the CSF. Atropine treatment decreased a-APPs levels by 38% (P = 0.05) compared to a-APPs levels in the saline treated group. When normal mice were treated with atropine plus RS86, changes in a-APPs levels were not detectable. NGF levels in the CSF were not signi®cantly changed by either atropine treatment or atropine plus RS86 treatment.
stimulation. These changes were also observed in the striatum (Fig. 2B , regression analysis: n = 14; P < 0.05), but not in the parietal or frontal cortex of the same animal. We could not detect a correlation between the levels of a-APPs and NGF in the CSF.
Discussion
Muscarinic receptor agonist or antagonist can modify APP levels and APP secretion
The administration of a muscarinic receptor agonist resulted in signi®cant decreases in total APP levels in the hippocampus and frontal cortex with parallel increases in a-APPs levels in the CSF, indicating that treatment with M1 receptor agonist enhances the asecretase pathway of APP in normal adult mice. This ®nding is consistent with previous reports in normal adult rats and rats with selective degeneration of cholinergic basal forebrain neurons (Farber et al., 1995; Lin et al., 1999) . Although we couldn't determine Ab levels directly in these mice, a-APPs is closely and inversely related to the formation of the Ab peptide and this data may be relevant for the understanding of amyloidogenic processing of APP (Lin et al., 1999) .
Other groups have reported effects of other selective M1 agonists on APP expression and processing in vitro. M1 agonists increase aAPPs release from PC12 cells (Buxbaum et al., 1992; Lee et al., 1995) , 293 cells, hippocampal slices and M1 transfected CHO cells (Muller et al., 1997; Muller et al., 1998) . Selective M1 agonists have been reported to decrease Ab levels in CHO cells (Wolf et al., 1995; DeLapp et al., 1998) . Recently, it was reported that total Ab is decreased in the CSF of Alzheimer's disease (AD) patients after chronic M1 agonist treatment (Hock et al. 2000; . In our study, treatment with a muscarinic antagonist (atropine) resulted in signi®cant increases in total APP levels in the hippocampus and frontal cortex as well as decreases in a-APPs levels in the CSF. A combined treatment with atropine and the M1 agonist signi®cantly reversed the APP changes induced by either the M1 agonist or atropine alone in these normal mice (Table 1 and Fig. 1) . However, the effect of atropine was not fully reversed by the M1 agonist, possibly due to differences in ligand speci®city for subtypes of muscarinic receptors; as RS86 is a selective M1 agonist and atropine is a general muscarinic antagonist (M1±M5) (Palacios et al., 1986; Wanibuchi et al., 1990; Rupniak et al., 1992) . This interpretation is supported by our CSF data, as in the atropine plus M1 agonist treatment group there were no changes in a-APPs levels, suggesting that the opposing effects of these cholinergic agents cancelled each other out. Consistent with our results, Beach et al., (1996) found that atropine treatment increased the levels of APP mRNA in rat cerebral cortex, dentate gyrus and CA1 region. Similarly, a series of experiments in brain slice cultures indicated that atropine treatment decreases a-APPs levels (Muller et al., 1997) . Thus, it appears that the expression, proteolytic processing and/or release of APP can be regulated by muscarinic receptor stimulation or blockade.
Nerve growth factor levels are reduced by chronic M1 muscarinic receptor agonist treatment in normal mice During early postnatal development, it has been reported that cholinergic activity in basal forebrain neurons may initially stimulate NGF synthesis in appropriate target areas (Whittemore et al., 1988; dePenha-Berxahi et al., 1993) . However, in the mature CNS, NGF effects are primarily seen on phenotypic maintenance of cholinergic basal forebrain neurons and also neuronal plasticity after injury (Korsching et al., 1985; Whittemore et al., 1986; Whittemore et al., 1988; Sofroniew, 1991; Conner et al., 1992; Sofroniew et al. 2001) . In this study of adult mice, administration of M1 agonist decreased the levels of NGF in the hippocampus and CSF. Importantly, these changes in NGF protein levels observed after chronic 7-days treatment (long-term) with an M1 agonist do not mirror the NGF mRNA or BDNF (brain-derived neurotrophic factor) changes seen after singular acute administrations (dePenha-Berxahi et al., 1993; Lapchak, 1993; French et al., 1999) , with effects seen within hours (short-term), of antagonist, muscarinic agonist or acetylcholine modifying drugs (Knipper et al., 1994; French et al., 1999) . The most likely explanation is that long-term M1 agonist delivery arti®cially and chronically overstimulates the postsynaptic cholinergic receptors thereby causing adaptive synaptic changes and compensatory decreased NGF levels. Short-term agonist treatment may elicit a neutral or positive trophic response while long-term (7 day) overactivation induces corrective reduced trophic signals in the septohippocampal cholinergic circuitry.
Recent data showing LTP (long-term potentiation) dependence on NGF, NGF/TrkA and the muscarinic cholinergic system is consistent with the interpretation of our APP and NGF ®ndings as adaptive responses of the corticohippocampal cholinergic synaptic system (Pesavento et al. 2000; Isacson et al. 2002) .
Interaction between the cholinergic system, APP and NGF: does neurotransmission regulate trophic homeostasis?
In the present study, the percentage decrease in the total APP levels were inversely related to the change in NGF levels in the hippocampus and striatum of the normal mouse suggesting a homeostatic feedback regulation of these proteins (Fig. 2) . Interestingly, a-APPs levels were increased in the CSF after cholinergic activation, which may indicate a lack of receptor complex binding of a-APPs in the hippocampal system, consistent with decreased neurotrophic tone. One possible postulate from these ®ndings is the existence of an equilibrium of NGF and APP levels, normally regulated by the cholinergic synaptic complex. Generally, NGF levels in the hippocampus are dependent both on expression and release of NGF by hippocampal neurons in the dentate gyrus, CA1±4 regions. For example, blockade of transport in dysfunctional cholinergic neurons leads to markedly increased NGF protein levels in the hippocampus in ageing, AD and possibly Down's syndrome (Crutcher et al., 1993; Mufson et al., 1995; Fahnestock et al., 1996; Calamandrei et al. 2000) . Thus, in our study, the chronic overstimulation of the M1 muscarinic receptor was negatively regulated by a compensatory reduction in trophic signals (NGF and a-APPs) to cholinergic afferent terminals in hippocampal and cortical ®elds. Conversely, atropine mediated cholinergic receptor blockade for 7 days elicited a positive compensatory trophic stimulation by a combined increase in total APP plus NGF levels (Table 1) . Indeed, in the atropine treated group, the combined total APP plus NGF protein levels of the hippocampus showed a twofold increase compared to those levels in control group. One possible interpretation of this elevation within the tissue is an increased a-APPs binding and internalization by cholinergic hippocampal terminals as an adapted positive trophic response (Mufson et al., 1995) .
It has been reported that in vitro, NGF initially promotes a-APPs secretion by M1 agonist treatment in M1 receptor transfected PC12 cell lines (Haring et al., 1995) . After exposure to NGF, primary cortical neuronal cultures showed increased levels of membrane phospholipids that may promote neurite formation, APP expression and secretion of a-APPs (Wang et al. 2000) . Acutely, in a growing cell culture system, APP gene expression is up-regulated by NGF by transactivating its promoter as shown in transient transfection experiments (Lahiri & Nall, 1995) . Treatment of PC12 cells with NGF also caused an increase in the steady-state levels of endogenous presenilin-1 (PS1) (Counts et al. 2001) , which is required for gsecretase activity to produce a-APPs. During trophic factor withdrawal-induced death of PC12 cells, APP expression was increased (Araki & Wurtman, 1998) . In agreement with the interpretation of our in vivo data, a-APPs synergistically potentiates the tyrosine phosphorylation of TrkA and modulates the interaction of NGF with the p75 NTR receptor (Akar & Wallace, 1998) . Conversely, the activation of TrkA (high-af®nity receptor for NGF) initially results in increased a-APPs in PC12 cell lines (Rossner et al., 1999) . Mobley et al., (1988) observed an acute increase in APP mRNA levels in the developing hamster brain after NGF administration. However, others have shown that NGF administration has no effect on APP mRNA or APP expression levels in the rat brain (Forloni et al., 1993; Neve et al., 1996) .
Muscarinic M1 stimulation could induce the expression of APP and/or secretion of a-APPs through the protein kinase C (PKC)-independent pathway activated by the NGF receptor. The retrograde transport of NGF is mediated by p75 NTR and plays a role in the recruitment of NGF and its presentation to high-af®nity receptors that modulate Trk signalling (Hantzopoulos et al., 1994; Verdi et al., 1994; MacPhee & Barker, 1997) . Stimulation of the p75 NTR induces expression of APP mRNA through activation of sphingomyelinase and via subsequent generation of ceramide and activation of NFkB (MacPhee & Barker, 1997) . Conversely, NGF binding to TrkA leads to suppression of APP mRNA expression through p21Ras activated signalling pathways involving MAP kinases and phosphatidylinositol 3-kinase. Secretory processing of APP is activated via a phospholipase Cg (PLCg) transduction cascade (Mills et al., 1997; Rossner et al., 1998) .
The regulation of APP and NGF protein levels in the corticohippocampal system: relevance to Alzheimer's disease a-APPs and NGF have important functions not only in trophic mechanisms but also neural transmission. a-APPs modulate neuronal excitability, counteract the effects of glutamate on growth cone behaviour and increase synaptic complexity (Mattson & Furukawa, 1998; Rossner et al., 1998) illustrating the functions of a-APPs as a trophic and modulatory factor. Nerve growth factor regulates the survival, differentiation and phenotypic maintenance of cholinergic basal forebrain neurons and also plays a role in neuronal plasticity after injury. Nerve growth factor treatment resulted in a drastic reduction in synaptophysin release in PC12 cells (Marquez-Sterling et al., 1997; Chapman et al., 1999) . In APP transgenic mice, mutant APP causes age-dependent learning impairment through disruption of synaptic plasticity (Chapman et al., 1999) . As learning and memory are thought to depend on changes in synaptic ef®cacy in certain key brain structures, including the hippocampus (Bliss & Collingridge, 1993; Chapman et al., 1999) , better understanding of the interaction of trophic factors, like a-APPs and NGF, with afferent hippocampal synapses will be of importance.
The alterations of APP expression, processing and secretion are closely related to the production of the Ab peptide, which is the principal constituent of senile plaques and cerebrovascular deposits in AD (Mattson & Furukawa, 1998; Rossner et al., 1998) . Recently, it has been reported that aged anti-NGF transgenic mice display pathological symptoms similar to AD, including amyloid plaques, insoluble and hyperphosphorylated tau, neuro®brillary tangles in cortical and hippocampal neurons, neuronal loss, cholinergic de®cits and behavioural de®cits (Capsoni et al. 2000 ). Alzheimer's disease patients show less TrkA NGF receptor mRNA levels than normal control subjects (Mufson et al., 1996) , reduced TrkA protein levels (Mufson et al., 1997; Salehi et al., 1998) , no change in NGF mRNA levels (Massaro et al., 1994; Hock et al., 1998) and an increase in hippocampal NGF protein levels (Crutcher et al., 1993; Fahnestock et al., 1996) .
Cortical cholinergic activation may also alter APP processing in favour of the generation of neurotrophic a-APPs and decreased production of amyloidogenic APP fragments. Recently, it was reported that M1 agonist treatment decreased total Ab levels in the CSF of AD patients (Hock et al. 2000; . The observed reduction in total APP levels in the normal hippocampus, increase in a-APPs levels in the CSF and reduction in NGF levels in the hippocampus and CSF after muscarinic agonist treatment demonstrates the normal regulation and interdependence of these factors. This may be relevant for our understanding of the appropriate physiological function of ACh, APP and NGF and their abnormal regulation and levels seen in AD and Down's syndrome.
